NEW HAVEN, Conn., March 6, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced senior management will attend and participate in the following March conferences.
Frazier/Fenwick Winter Investor Event
Dates: March 7-10, 2023
Oppenheimer 33rd Annual Healthcare Conference (March 13-15, 2023)
Presentation Date/Time: Monday, March 13 at 4:00 p.m. ET
Corporate presentation: Jennifer Good, President and CEO, and Lisa Delfini, CFO
BIO-Europe Spring
Dates: March 20-22, 2023 (in-person) and March 28-30, 2023 (virtual)
Location: Basel, Switzerland and virtual
For more information or to register, please click here.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational oral therapy Haduvio™ (nalbuphine ER) for the treatment of chronic cough in adults with IPF, other chronic cough indications, and for the treatment of prurigo nodularis. The Company reported statistically significant results from the Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in adults with IPF. Based on this positive data, Trevi plans to focus future clinical development on chronic cough conditions, including IPF, refractory chronic cough, and interstitial lung diseases (ILDs).
For more information, visit www.TreviTherapeutics.com and follow the Company on Twitter and LinkedIn.
Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Rosalia Scampoli
914-815-1465
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$6.07 |
| Daily Change: | -0.03 -0.49 |
| Daily Volume: | 681,580 |
| Market Cap: | US$542.480M |
March 18, 2025 February 25, 2025 December 03, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
